middle.news
How Tetratherix Plans to Turn $29.3M Cash into Commercial Success After $9.4M Loss
2:16am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
How Tetratherix Plans to Turn $29.3M Cash into Commercial Success After $9.4M Loss
2:16am on Saturday 30th of August, 2025 AEST
Key Points
Statutory loss of $9.4 million and underlying loss of $4.6 million in FY25
Strong cash position of $29.3 million with zero debt after $36 million capital raise
Key agreements signed with Henry Schein and BioOptix; three FDA pre-submissions completed
R&D expenditure up 24%, focused on bone regeneration, tissue spacing, and healing franchises
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Tetratherix (ASX:TTX)
OPEN ARTICLE